Sulesomab Biosimilar – Anti-NCA-90 mAb – Research Grade

Description of Sulesomab Biosimilar - Anti-NCA-90 mAb - Research Grade

Sulesomab Biosimilar: A Revolutionary Antibody for Targeting NCA-90

Sulesomab Biosimilar, also known as Anti-NCA-90 mAb, is a novel monoclonal antibody that has been developed as a biosimilar to the original sulesomab antibody. This biosimilar has been designed to target NCA-90, a cell surface protein that is overexpressed in various types of cancer, making it a promising therapeutic target for cancer treatment.

Structure of Sulesomab Biosimilar

Sulesomab Biosimilar is a recombinant monoclonal antibody that is produced using advanced biotechnology methods. It is composed of two identical heavy chains and two identical light chains, each with a molecular weight of approximately 150 kDa. The heavy chains are connected to each other by disulfide bonds, while the light chains are connected to the heavy chains by disulfide bonds and non-covalent interactions. The variable regions of the antibody, responsible for binding to NCA-90, are located at the tips of the heavy and light chains.

The structure of Sulesomab Biosimilar is highly specific and precise, allowing it to bind to NCA-90 with high affinity and specificity. This specificity is crucial for the effectiveness of the antibody as a therapeutic agent.

Activity of Sulesomab Biosimilar

The main activity of Sulesomab Biosimilar is its ability to bind to NCA-90 on the surface of cancer cells. NCA-90 is a glycoprotein that is overexpressed in various types of cancer, including breast, lung, and colon cancer. By binding to NCA-90, Sulesomab Biosimilar blocks its function and disrupts the signaling pathways that promote cancer growth and survival.

In addition, Sulesomab Biosimilar also activates the immune system to target and destroy cancer cells. This is achieved through the antibody’s ability to recruit immune cells, such as natural killer cells and macrophages, to the site of the cancer. These immune cells then work together to eliminate the cancer cells, providing a powerful anti-tumor effect.

Application of Sulesomab Biosimilar

Sulesomab Biosimilar has shown great potential in preclinical studies as a therapeutic agent for various types of cancer. Its unique mechanism of action, targeting NCA-90 and activating the immune system, makes it a promising candidate for cancer treatment. In fact, clinical trials have already been initiated to evaluate the safety and efficacy of Sulesomab Biosimilar in cancer patients.

Furthermore, Sulesomab Biosimilar has also been used in research settings to study the role of NCA-90 in cancer and to develop new diagnostic and therapeutic strategies. Its availability as a research grade antibody allows scientists to easily access and utilize this powerful tool in their studies.

Conclusion

Sulesomab Biosimilar is a revolutionary antibody that specifically targets NCA-90, a cell surface protein that is overexpressed in various types of cancer. Its unique structure and activity make it a promising therapeutic agent for cancer treatment, with potential applications in both clinical and research settings. As research and clinical trials continue to explore the potential of Sulesomab Biosimilar, it is clear that this antibody has the potential to make a significant impact in the fight against cancer.